{
    "clinical_study": {
        "@rank": "9778", 
        "arm_group": [
            {
                "arm_group_label": "Metformin + Sitagliptin + Glimepiride", 
                "arm_group_type": "Active Comparator", 
                "description": "During Phase 2, participants receive up to 6 mg glimepiride daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44)."
            }, 
            {
                "arm_group_label": "Metformin + Sitagliptin + Repaglinide", 
                "arm_group_type": "Experimental", 
                "description": "During Phase 2, participants receive up to 16 mg repaglinide daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44)."
            }, 
            {
                "arm_group_label": "Metformin + Sitagliptin + Acarbose", 
                "arm_group_type": "Experimental", 
                "description": "During Phase 2, participants receive 50-100 mg acarbose three times daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44)."
            }, 
            {
                "arm_group_label": "Metformin + Sitagliptin + Gliclazide", 
                "arm_group_type": "Experimental", 
                "description": "During Phase 2, participants receive 30-120 mg gliclazide daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44)."
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the effect of adding acarbose or repaglinide or gliclazide to sitagliptin plus\n      metformin, compared to adding glimepiride, on glycemic improvements in Type 2 Diabetes\n      Mellitus (T2DM) participants who require the addition of a third oral anti-hyperglycemic\n      agent (OAHA) according to China Guideline for Type 2 Diabetes. The three co-primary\n      hypotheses are that after 24 weeks of treatment in phase 2, the mean change from baseline in\n      hemoglobin A1c (A1c) in participants receiving either (1)acarbose or (2)repaglinide or\n      (3)gliclazide added to sitagliptin and metformin combination is non-inferior to that of\n      participants receiving glimepiride added to sitagliptin and metformin combination."
        }, 
        "brief_title": "Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313 AM1)", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "Participants coming on study will be stabilized to a standardized metformin dose: this may\n      take about 10 weeks, and then combination therapy with metformin + sitagliptin will begin\n      during Phase 1 (Week 0 through Week 20).  If a participant is already on a stabilized\n      metformin dose, they will start immediately on combination therapy with metformin +\n      sitagliptin for 20 weeks (Phase 1).\n\n      In Phase 2, participants who have failed to achieve adequate glycemic control (A1c \u2265 7% and\n      \u2264 10% at Week 16 and fasting finger stick glucose \u2265130 mg/dL and \u2264280 mg/dL at Week 20) will\n      be randomized to receive add-on therapy with glimepiride, repaglinide, acarbose, or\n      gliclazide for 24 weeks (Week 20 through Week 44)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Has Type 2 Diabetes Mellitus\n\n          -  Agrees to use an effective method of contraception or must not otherwise be at risk\n             of becoming pregnant (female participants)\n\n        Exclusion Criteria:\n\n          -  Has a history of type 1 diabetes mellitus or a history of ketoacidosis\n\n          -  Has been treated with insulin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, a\n             Glucagon-like peptide-1 (GLP-1) mimetic or analogue before\n\n          -  Is on a weight loss program (not in maintenance phase), has started a weight loss\n             medication, or has undergone bariatric surgery within 12 months\n\n          -  Has undergone a surgical procedure within 4 weeks\n\n          -  Has had new or worsening signs or symptoms of coronary heart disease\n\n        or congestive heart failure within past 3 months, or has acute coronary syndrome, coronary\n        artery intervention, or stroke or transient ischemic neurological disorder\n\n          -  Has a medical history of active liver disease, including chronic active hepatitis B\n             or C, primary biliary cirrhosis, or symptomatic gallbladder disease\n\n          -  Has poorly controlled hypertension\n\n          -  Has severe peripheral vascular disease\n\n          -  Has human immunodeficiency virus (HIV)\n\n          -  Has had a clinically important hematological disorder\n\n          -  Routinely consumes >2 alcoholic drinks per day or >14 alcoholic drinks\n\n        per week, or engages in binge drinking.\n\n          -  Has a history of intolerance or hypersensitivity or any contraindication to\n\n        study medications (including sitagliptin, metformin, glimepiride, repaglinide,\n\n        acarbose or gliclazide) based upon the Chinese label\n\n          -  Is on or likely to require treatment with \u22652 consecutive weeks or\n\n        repeated courses of pharmacologic doses of corticosteroids (other than inhaled, nasal, or\n        topical corticosteroids)\n\n          -  Is pregnant or breast feeding or is expecting to conceive or donate eggs\n\n        during the study, including 14 days following the last dose of study drug (female\n        participants)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "5500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01709305", 
            "org_study_id": "0431-313"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Metformin + Sitagliptin + Glimepiride", 
                    "Metformin + Sitagliptin + Repaglinide", 
                    "Metformin + Sitagliptin + Acarbose", 
                    "Metformin + Sitagliptin + Gliclazide"
                ], 
                "description": "Metformin, 500 mg or 850 mg oral tablets, twice or three times a day (BID or TID) for a total dose of at least 1500 mg daily", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Fortamet\u00ae", 
                    "Glucophage\u00ae", 
                    "Glucophage\u00ae XR", 
                    "Glumetza\u00ae", 
                    "Riomet\u00ae", 
                    "Metgluco\u00ae", 
                    "Glycoran\u00ae"
                ]
            }, 
            {
                "arm_group_label": [
                    "Metformin + Sitagliptin + Glimepiride", 
                    "Metformin + Sitagliptin + Repaglinide", 
                    "Metformin + Sitagliptin + Acarbose", 
                    "Metformin + Sitagliptin + Gliclazide"
                ], 
                "description": "Sitagliptin, 100 mg oral tablet, once daily (QD)", 
                "intervention_name": "Sitagliptin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Januvia\u00ae", 
                    "Tesavel\u00ae", 
                    "Xelevia\u00ae", 
                    "Ristaben\u00ae"
                ]
            }, 
            {
                "arm_group_label": "Metformin + Sitagliptin + Acarbose", 
                "description": "Acarbose, 50 mg oral tablets, TID (150 mg total daily dose)", 
                "intervention_name": "Acarbose", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Precose\u00ae", 
                    "Glucobay\u2122"
                ]
            }, 
            {
                "arm_group_label": "Metformin + Sitagliptin + Repaglinide", 
                "description": "Repaglinide, 0.5 mg and/or 1 mg oral tablets, TID (up to 16 mg daily)", 
                "intervention_name": "Repaglinide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Prandin\u00ae", 
                    "Fulaidi\u2122"
                ]
            }, 
            {
                "arm_group_label": "Metformin + Sitagliptin + Glimepiride", 
                "description": "Glimepiride, 1 mg and/or 2 mg oral tablets, QD (up to 6 mg daily)", 
                "intervention_name": "Glimepiride", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Amaryl\u00ae", 
                    "Glimy"
                ]
            }, 
            {
                "arm_group_label": "Metformin + Sitagliptin + Gliclazide", 
                "description": "Gliclazide, 30 mg oral tablets, QD or BID (30 mg to 120 mg total daily dose)", 
                "intervention_name": "Gliclazide", 
                "intervention_type": "Drug", 
                "other_name": "Diamicron MR\u2122"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glimepiride", 
                "Repaglinide", 
                "Sitagliptin", 
                "Gliclazide", 
                "Metformin", 
                "Acarbose"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 9, 2014", 
        "number_of_arms": "4", 
        "official_title": "A Multicenter, Randomized, Active-Controlled, Open-label Clinical Trial to Evaluate the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose as a Third OAHA on Top of Sitagliptin+Metformin Combination Therapy in Chinese Patients With Type 2 Diabetes Mellitus (Phase IV; Protocol No. MK-0431-313-01)", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change From Phase 2 Baseline to Week 44 in Hemoglobin A1c (HbA1c) Levels (Phase 2)", 
            "safety_issue": "No", 
            "time_frame": "Phase 2 Baseline (Week 20), Week 44"
        }, 
        "removed_countries": {
            "country": "China"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01709305"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change From Phase 2 Baseline to Week 44 in Participant Body Weight (Phase 2)", 
                "safety_issue": "Yes", 
                "time_frame": "Phase 2 Baseline (Week 20), Week 44"
            }, 
            {
                "measure": "Number of Participants With Hypoglycemia Events (Phase 2)", 
                "safety_issue": "Yes", 
                "time_frame": "From Week 20 through Week 44"
            }, 
            {
                "measure": "Number of Participants With Gastrointestinal Adverse Events (Phase 2)", 
                "safety_issue": "Yes", 
                "time_frame": "From Week 20 through Week 44"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}